Skip to main content
. 2025 Jan 23;57(3):621–634. doi: 10.4143/crt.2024.1222

Fig. 1.

Fig. 1.

Evolving decision-making in stage II/III gastric cancer: current practices and future direction. ctDNA, circulating tumor DNA; EBV, Epstein-Barr virus; IM, immune; MSI-H, microsatellite instability–high; XELOX, capecitabine plus oxaliplatin.